Reported a net loss of $8.8 million, or $0.78 per share, for the fiscal year ended December 31, 2025, a significant reduction from the $17.5 million net loss ($1.72 per share) in 2024. Research and development expenses decreased to $5.1 million in 2025 from $12.5 million in 2024, primarily due to the winddown of the Phase 2a influenza study. General and administrative expenses decreased to $4.0 million in 2025 from $5.3 million in 2024. Unrestricted cash stood at $7.7 million as of December 31, 2025, down from $9.9 million at the end of 2024. Net cash used in operating activities for 2025 was $8.2 million, a reduction from $16.5 million in 2024. The Phase 1b human challenge study for CDI-988, an oral antiviral candidate for norovirus, is underway at Emory University School of Medicine. The initial Phase 2a study for influenza candidate CC-42344 was completed, showing a favorable safety and tolerability profile, but efficacy analyses were not reported due to issues with trial conduct. Received a $500,000 Small Business Innovation Research Phase I award from the NIHs National Institute of Allergy and Infectious Diseases for a novel influenza A/B program.